Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report.
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
19
12
2019
revised:
07
02
2020
accepted:
24
02
2020
entrez:
28
3
2020
pubmed:
28
3
2020
medline:
28
3
2020
Statut:
epublish
Résumé
•There is a critical need for therapeutic options in uterine serous carcinoma (USC).•A substantial proportion of USC cases express estrogen receptors (ER).•This report describes use of letrozole therapy in recurrent, ER-positive USC.•Zoledronic acid may enhance letrozole efficacy against hormone-sensitive tumors.•Aromatase inhibitors could be a potential treatment option in ER-positive USC.
Identifiants
pubmed: 32215315
doi: 10.1016/j.gore.2020.100555
pii: S2352-5789(20)30021-7
pii: 100555
pmc: PMC7091228
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100555Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
Dr. Stephanie Gaillard reports the following disclosures outside of the submitted work: grants and personal fees from Merck, Tesaro, Pfizer, Genentech/Roche, PharmaMar; grants to institution from Abbvie, Bristol-Myers Squibb, Gradalis, Iovance Biotherapeutics, Tetralogic Pharmaceuticals; personal fees from AstraZeneca and Immunogen. Otherwise, the authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.
Références
Gynecol Oncol. 2015 Sep;138(3):620-6
pubmed: 26123645
J Clin Oncol. 2018 Jul 10;36(20):2044-2051
pubmed: 29584549
Oncotarget. 2017 Jan 3;8(1):506-511
pubmed: 27888807
Semin Oncol. 2010 Jun;37 Suppl 1:S53-65
pubmed: 20682373
Ann Oncol. 2013 Feb;24(2):398-405
pubmed: 23047045
Cancer Sci. 2012 May;103(5):926-32
pubmed: 22329832
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Gynecol Oncol. 2004 Jan;92(1):10-4
pubmed: 14751131
J Clin Oncol. 2015 Mar 10;33(8):930-6
pubmed: 25624430